Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 16;192(10):4813–4820. doi: 10.4049/jimmunol.1303369

Figure 3. Assessment of C. rodentium-associated disease in EPS or TLR4 agonist-treated TLR4 KO or wt mice.

Figure 3

Quantification by ELISA of pro-inflammatory KC in serum of TLR4 KO mice infected with C. rodentium (Cr) with or without EPS (EPS+); PBS and EPS+ are negative controls (A). Summary of colonic crypt heights from each treatment group (B). Diarrhea (C) also served as a disease marker. Results are averages from at least three independent experiments; a total of 5–10 mice were assessed for each group. (D–F): Wt mice were treated with 50, 100, or 150 μg of the TLR4 agonist hyaluronic acid (HA) prior to infection and then assessed for disease 10 dpi. Serum KC was measured by ELISA (D), colonic crypt heights from each treatment group were measured (E), and diarrhea (F) also served as a disease marker. Results are averages from at two independent experiments; a total of 4–5 mice were assessed for each group.

HHS Vulnerability Disclosure